Dermatomycoses: Clinical Trials

76 trials for Dermatomycoses, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

55 completed, 10 unknown, 4 not yet recruiting, 2 active not recruiting. 76 Phase 2, 7 Phase 3, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 276Completed 55, Unknown 10, Not yet recruiting 4, Active not recruiting 2, Recruiting 2, Suspended 1, Terminated 1, Withdrawn 1
Phase 37Completed 4, Unknown 2, Active not recruiting 1
Phase 14Completed 3, Not yet recruiting 1

Follow Dermatomycoses: new trials by email Literature Review of Dermatomycoses trials Research Report on Dermatomycoses

Trials (filtered) newest first · largest first

All 76 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Platform Trial for Salvage Consolidation Therapy in Dimorphic Fungi
Oteseconazole - Coccidioidomycosis, Blastomycosis
Phase 2Not yet recruitingUniversity of Minnesota302026-12-012026-09-04
Safety and Efficacy Study of SKX-16 in Participants With Mild to Moderate Distal Subungual Onychomycosis
SKX-16 (Luliconazole 10% Solution), Vehicle solution - Onychomycosis of Toenails
Phase 2Not yet recruitingSATO Pharmaceutical Co., Ltd.2042026-11-242026-11-10
Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor
Topical 1 % clotrimazole twice daily 2 weeks, Oral itraconazole 200mg daily for 5 days - Pityriasis Versicolor
Phase 1 / Phase 2Not yet recruitingCombined Military Hospital Abbottabad862026-02-022026-01-12
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
Trichostatin A - Onychomycosis of Toenail
Phase 2Active not recruitingVanda Pharmaceuticals502025-05-052026-02-04
Efficacy and Safety of Topical Amphotericin B Solution in Treatment of Resistant Tinea Capitis in Children 16 Years Old or Less we Follow up Cases Weekly up to 8 Weeks and Notice Improvement of Itching ,Scaling, and Hair Regrowth Then Fungal Culture Done to See if the Solution Working
Amphotericine in liposome (Ambisome®) - Tinea Capitis
Phase 2 / Phase 3Active not recruitingSohag University302025-04-012025-05-20
Topical Tolnaftate Stick for Tinea Pedis: An Open-Label Interventional Study
1% Tolnaftate Stick Formula A, 1% Tolnaftate Stick Formula B, 1% Tolnaftate Stick Formula C - Tinea Pedis
Phase 2RecruitingPropedix, Inc.1502024-12-302025-11-28
Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections
Voriconazole high dose, Voriconazole low dose - Dermatophyte Infection
Phase 2Not yet recruitingSheikh Zayed Medical College1202024-11-152024-11-08
A Study of ATB1651 in Adults With Mild to Moderate Onchomycosis
ATB1651-102- Cohort 1, ATB1651-102- Cohort 2, ATB1651-102- Cohort 3 - Onychomycosis
Phase 2RecruitingAmtixBio Co., Ltd.1202024-07-012025-02-19
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis
DBI-001, DBI-002, Aqueous Gel - Onychomycosis
Phase 2SuspendedDermBiont, Inc.602023-11-012023-09-07
Efficacy and Safety of Terbinafine and Itraconazole
Terbinafine Tablets, Itraconazole - Tinea Corporis, Tinea Cruris
Phase 2 / Phase 3UnknownDhaka Medical College1502023-05-012023-05-31
Pilot Study of Swift Microwave Device for Onychomycosis
Swift Microwave treatment - weekly x 4wks, Swift Microwave treatment - Every other week x 4wks, Swift Microwave treatment - Every other week x 24wks - Onychomycosis of Toenail
Phase 1 / Phase 2CompletedMediprobe Research Inc.392023-03-272024-11-18
A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis
DBI-001 Gel, DBI-002 Gel, Aqueous Gel - Tinea Pedis
Phase 2UnknownDermBiont, Inc.242022-09-082023-02-14
To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis
Hallux Terbinafine Subungual Gel - Onychomycosis of Toenail
Phase 2UnknownHallux, Inc.352022-01-132023-08-07
A Trial Involving Treatment of BB2603 in Subjects With Distal Subungual Onychomycosis of the Toenail
BB2603-1, BB2603-3, BB2603-10 - Distal Subungual Onychomycosis, Fungal Infection
Phase 2CompletedBlueberry Therapeutics1112021-03-222023-08-01
A Trial to Evaluate the Safety and Antimicrobial Efficacy of DBI-002 Probiotic in Adults With Tinea Versicolor
DBI-002 probiotic gel, Aqueous gel - Tinea Versicolor
Phase 2CompletedDermBiont, Inc.342021-03-162025-07-03
Systemic Uptake of Diclofenac Sodium in Combination With Miconazole as Antifungal Nail Gel When Applied Daily With Monitoring of Hepatic and Renal Enzymes, and Serum Levels of Diclofenac 12 Hours After Application, and at 3 and 6 Months Study
Antifungal Nail Gel Study - Tinea Unguium, Onychomycosis
Phase 2UnknownWilliam N Handelman302020-05-012020-04-10
A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis
UHE-103A1 cream, UHE-103A2 cream, UHE-103B cream - Tinea Pedis
Phase 2CompletedTherapeutics, Inc.2402019-03-152021-10-28
A Trial to Evaluate the Safety and and Tolerability of DBI-001 in Patients With Tinea Pedis
Janthinobacterium lividum - Tinea Pedis
Phase 2CompletedDermBiont, Inc.122019-02-192025-06-17
SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS
TERBINAFINE HYDROCHLORIDE (1%), BUTENAFINE HYDROCHLORIDE (1%), Vehicle Control - Tinea Pedis
Phase 2UnknownUnited Laboratories422019-01-022019-06-26
Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
SUBA itraconazole, Conventional itraconazole - Invasive Fungal Infections
Phase 2 / Phase 3CompletedUniversity of Alabama at Birmingham882018-09-172023-07-07

Showing 20 of 76. Sign in to see all of them.

Narrower conditions

Onychomycosis (40)  ·  Tinea Pedis (17)  ·  Mycoses (6)  ·  Tinea (6)  ·  Blastomycosis (4)  ·  Histoplasmosis (4)  ·  Tinea Versicolor (4)  ·  Communicable Diseases (3)  ·  Rare Diseases (3)  ·  Sporotrichosis (3)  ·  Tinea Capitis (3)  ·  Tinea Cruris (3)  ·  Coccidioidomycosis (2)  ·  Immune System Diseases (2)

Broader conditions

Bacterial Infections and Mycoses (76)  ·  Skin Diseases, Infectious (76)  ·  Skin and Connective Tissue Diseases (76)  ·  Infections (75)  ·  Skin Diseases (75)  ·  Mycoses (70)  ·  Tinea (59)  ·  Nail Diseases (40)  ·  Pathological Conditions, Signs and Symptoms (22)  ·  Signs and Symptoms (17)  ·  Skin Manifestations (17)  ·  Foot Dermatoses (16)  ·  Foot Diseases (16)  ·  Pruritus (16)

Interventions

Terbinafine (8)  ·  Itraconazole (7)  ·  tavaborole (5)  ·  BANG polymer gel (3)  ·  1-(2-(2,4-dichlorophenyl)-2-(4-(trifluoromethyl)benzyloxy)ethyl)-1H-imidazole (2)  ·  Fluconazole (2)  ·  Miconazole (2)  ·  Nitric Oxide (2)  ·  VT-1161 (2)  ·  Albendazole (1)  ·  Amphotericin B (1)  ·  Ciclopirox (1)  ·  Diclofenac (1)  ·  Econazole (1)  ·  Exercise (1)

Sponsors

Pfizer (7)  ·  DermBiont, Inc. (4)  ·  Nitric BioTherapeutics, Inc (4)  ·  Hallux, Inc. (2)  ·  National Center for Research Resources (NCRR) (2)  ·  Nomir Medical Technologies (2)  ·  Sara Botros (2)  ·  Sun Pharmaceutical Industries, Inc. (2)  ·  Topica Pharmaceuticals (2)  ·  Viamet (2)  ·  9305-9954 Quebec Inc (1)  ·  Abeona Therapeutics, Inc (1)  ·  Almirall, S.A. (1)  ·  AmDerma (1)  ·  AmtixBio Co., Ltd. (1)

Countries

United States (37)  ·  Canada (9)  ·  Germany (4)  ·  Mexico (4)  ·  Egypt (3)  ·  Brazil (2)  ·  Dominican Republic (2)  ·  Czechia (1)  ·  El Salvador (1)  ·  Iceland (1)  ·  India (1)  ·  New Zealand (1)  ·  Pakistan (1)  ·  Panama (1)  ·  Philippines (1)

Top investigators

William Dismukes (3)  ·  Phoebe Rich, MD (2)  ·  Sara R Botros, bachelor of clinical pharmacy (2)  ·  Aditya Gupta, MD,PhD (1)  ·  Ahmed Fahal, Prof (1)  ·  Alan Robbins, M.D. (1)  ·  Alexandra Freeman, MD (1)  ·  Alicia Barba, MD (1)  ·  Alicia Bucko, DO (1)  ·  Andrej Spec, MD (1)  ·  Bernard Goffe, MD (1)  ·  Boni Elewski, MD (1)

Results publications

PMID 21967490, PMID 23377392, PMID 24173203, PMID 27297276, PMID 30526582, PMID 32421854, PMID 32457106, PMID 35699443, PMID 38440302, PMID 39098321, PMID 39624747, PMID 40433693

NIH funding

2008 (1), 2009 (1)